Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Chesnara plc is a public limited company specializing in life assurance and pensions consolidation across Europe. Headquartered in Preston, Lancashire, United Kingdom, it operates as a holding company that acquires and manages closed books of life and pension policies, primarily in the UK, Sweden, and the Netherlands. Established in 2004 through the demerger of Countrywide's life assurance business, Chesnara plc has grown via strategic acquisitions, including City of Westminster Assurance in 2007, Save & Prosper Group in 2010, Legal & General's Dutch business in 2017, Robein Leven in 2021, Canada Life's UK bonds and legacy pensions in 2024, and most recently, HSBC Life's UK life assurance business in January 2026. Led by Chief Executive Officer Steve Murray and Chairman Luke Savage, the company employs around 378 people and focuses on optimizing mature policy portfolios. As a FTSE 250 constituent, Chesnara plc plays a vital role in the insurance sector by providing efficient management solutions for legacy assurance and pensions products, enhancing value for policyholders and shareholders alike.
£3.37
+£0.02 (+0.60%)
EOD Jul 3, 2026
The institution is unprofitable. This typically signals severe credit losses or a business in transition.
Revenue declined 41.7% YoY. For a bank, this often signals contracting loan book or reduced fee income.
Net income declined 367% YoY, profitability momentum has weakened.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
£897M
▼ -41.7% YoY
Net Income (TTM)
-£10M
▼ -366.7% YoY
Net Margin
-1.16%
P/E
—
Balance Sheet
Total Assets
£14.58B
Equity
£563M
Total Debt
£205M
Cash & Equiv.
£145M
Continue Research
Chesnara (CSN.XLON)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Chesnara scores 38/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 7.2%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Chesnara scores 38 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Chesnara pays a regular dividend of about £0.24 per share per year (typically in quarterly installments), a yield of roughly 7.2% at the current price. Chesnara has grown the dividend at roughly 6.0% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For CSN.XLON's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. you should weigh CSN.XLON's valuation and scores 38/100 on quality (lower-quality). It also yields about 7.2%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.